The augmented expression of the cytidine deaminase gene by 5-azacytidine predicts therapeutic efficacy in myelodysplastic syndromes

5-Azacytidine (5AC), a hypomethylating agent, is clinically used for the treatment of patients with myelodysplastic syndromes (MDS). Cytidine deaminase (CDA) is a key enzyme in the detoxification of 5AC. We investigated whether the CDA expression could predict response to 5AC in MDS. Among leukemia-...

Descripción completa

Detalles Bibliográficos
Autores principales: Murakami, Yuichi, Kimura, Yoshizo, Kawahara, Akihiko, Mitsuyasu, Shohei, Miyake, Hidetoshi, Tohyama, Kaoru, Endo, Yoshio, Yoshida, Nao, Imamura, Yutaka, Watari, Kosuke, Ono, Mayumi, Okamura, Takashi, Kuwano, Michihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481348/
https://www.ncbi.nlm.nih.gov/pubmed/31040918
http://dx.doi.org/10.18632/oncotarget.26784

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481348/
https://www.ncbi.nlm.nih.gov/pubmed/31040918
http://dx.doi.org/10.18632/oncotarget.26784

Ejemplares similares